Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048750 · ClinicalTrials.gov registry record · Phase 3
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU
A Phase 3 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT00048750 is a Phase 3 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 104 participants.
The verdict
NCT00048750, a Phase 3 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.
Interventions
- DRUG Placebo
- DRUG Micafungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048750
The ClinicalTrials.gov registry entry for NCT00048750 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00048750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048750 about?
NCT00048750 is a clinical study titled "Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU". The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.
What is the current status of trial NCT00048750?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2003-01. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00048750?
The interventions under investigation include: Placebo (DRUG), Micafungin (DRUG).
Who is sponsoring clinical trial NCT00048750?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.